請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43634
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺 | |
dc.contributor.author | Fei-Chiao Kuo | en |
dc.contributor.author | 郭斐荍 | zh_TW |
dc.date.accessioned | 2021-06-15T02:24:49Z | - |
dc.date.available | 2019-12-31 | |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-18 | |
dc.identifier.citation | 1. Information received from the Internet Hompage of laboratoire d'etude de la neurodegenerscence. http://len.epfl.ch/page46792.html
2. Siderowf, A.; Stern, M. Update on Parkinson Disease. Ann. Intern. Med. 2003, 138, 651–658. 3. Meek, P. K.; McKeithan, K; Schumock, G. T. Economic considerations in Alzheimer’s disease. Pharmacotherapy, 1998, 18, 68–73. 4. Lewin Group. 2001. Medicare and Medicaid Costs for People with Alzheimer’s Disease. Alzheimer’s Association. http://www.alz.org/Media/newsreleases/alzreport.pdf 5. Online Mendelian inheritance in man (OMIM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University, National Center for Biotechnology Information, National Library of Medicine, Bethesda. http://www.ncbi.nlm.nih.gov/omim/ 6. Calabrese, E. J. Enhancing and Regulating Neurite Outgrowth. Crit. Rev. Toxicol. 2008, 38, 391–418. 7. Conti, A. M; Brimijoin, S.; Miller, L. J.; Windebank, A. J. Suppression of neurite outgrowth by high-dose nerve growth factor independent of functional p75NTR receptors. Neurobiol. Dis. 2004, 15, 106–114. 8. Rother, K. I. Diabetes Treatment — Bridging the Divide. N. Engl. J. Med. 2007, 356, 1499–1501. 9. Tierney, L. M.; McPhee, S. J.; Papadakis, M. A. Current medical Diagnosis & Treatment. International edition. New York: Lange Medical Books/McGraw-Hill. 2002, pp. 1203–1215. 10. Kruger, D. F. Exploring the Pharmacotherapeutic Options for Treating Type 2 Diabetes. Diabetes Educ. 2008, 34, 60S-65S. 11. Bloomgarden, Z. T. Insulin resistance, dyslipidemia, and cardiovascular disease. Diabetes Care. 2007, 30, 2164–2170. 12. Doupis, J.; Veves, A. DPP-4 Inhibitors: a New Approach in Diabetes Treatment. Adv. Ther. 2008, 25, 627–643. 13. Jun Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S.W.; Kassel, D. B,; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R; Gwaltney, S. L. Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV. J. Med. Chem. 2007, 50, 2297-2300. . 14. Moroz, N.; Tong, M.; Longato, L.; Xu, H.; Monte, S. M. Limited Alzheimer-Type Neurodegeneration in Experimental Obesity and Type 2 Diabetes Mellitus. J. Alz. Dis. 2008, 15, 29–44. 15. Ristow, M. Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 2004, 82, 510–529. 16. Drucker, D. J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003, 26, 2929–2940. 17. Deacon, C. F.; Nauck, M. A.; Toft-Nielsen, M.; Pridal, L.; Willms, B.; Holst, J. J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995, 44, 1126-1131. 18. Richter, B.; Bandeira-Echtler, E.; Bergerhoff, K.; Lerch, C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc. Health Risk Manag. 2008, 4, 753-768. 19. Information adapted from the Internet Hompage of Faming Zhang Research Group, which cited from Pharmacological Science, http://www.indiana.edu/~zhangweb/pages/research.php 20. Tanaka-Amino, K.; Hatakeyama1, Y.; Takakura, S.; Mutoh, S. Constitutive increase in active GLP-1 levels by the DPP-4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats. Pharmacol. Res. 2009, doi:10.1016/j.phrs.2009.03.018 21. During, M. J.; Cao, L.; Zuzga, D. S.; Francis, J. S.; Fitzsimons, H. L.; Jiao, X.; Bland, R. J.; Klugmann, M.; Banks, W. A.; Drucker, D. J.; Haile, C. N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9, 1173–1179. 22. Perry, T.; Lahiri, D. K.; Chen, D.; Zhou, J.; Shaw, K. T.; Egan, J. M.; Greig, N. H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 2002, 300, 958–966. 23. Biswas, S. C.; Buteau, J.; Greene, L. A. Glucagon-like Peptide-1 (GLP-1) Diminishes Neuronal Degeneration and Death Caused by NGF Deprivation by Suppressing Bim Induction. Neurochem. Res. 2008, 33, 1845–1851. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43634 | - |
dc.description.abstract | 本研究主旨在於設計與合成isoquinolinone 衍生物作為調控神經軸突之藥物以及糖尿病的抑制劑。以methyl 2-cyanomethylbenzoate (10)作為起始物,氫氧化鈉水溶液水解得到2-cyanomethylbenzoic acid (9),再以secondary amine 作親核加成,經電子轉移得到isoquinolinone類似物 (8, 17, 18, 19)。化合物8四號碳上的取代可用NXS作鹵素取代;或用氫化鈉拔去二號氮上的氫,再經電子轉移,在四號碳上作親核加成,用以接上拉電子基團。Quinazoline類似物則是以methyl 2-aminobenzoate (36)作為起始物,在高溫下和尿素反應,環化成quinazoline-2,4(1H,3H)-dione (37),再以三氯氧磷作氯化反應得到2,4-dichloroquinazoline (38),四號碳上的氯經由氫氧化鈉水溶液水解為羰基,quinazoline二號碳上的取代則是以酒精在封管、高溫下和二級胺反應 (43)。經體外神經細胞實驗及DPP 4 活性測試中發現,3-(piperidin-1-yl)isoquinolin-1(2H)-one (17)及其類似物,(R)-3-(3-(N-Boc-amino)piperidin-1-yl)isoquinolin-1(2H)-one (8),於sub-μM 濃度範圍內能顯著地促進神經軸突延長的現象,卻無法有效抑制DPP 4 的活性。具有此種類似結構之化合物亦有促進神經軸突延展之功能,未來經進一步優化後能更有效地應用於對抗神經退化性疾病以及糖尿病的治療。 | zh_TW |
dc.description.abstract | This thesis is aimed to majorly design a series of isoquinolinone derivatives as neurite outgrowth modulators and perhaps also as dipeptidyl peptidase 4 (DPP 4) inhibitor. The synthesis of isoquinolinone derivatives were started from commercially available methyl 2-cyanomethylbenzoate (10) which was hydrolyzed by sodium hydroxide to give 2-cyanomethylbenzoic acid (9). Subsequently, compound 9 was condensed with a variety of amines to afford isoquinolinone derivatives (8, 17, 18, and 19). The treatment of compound 8 with alkyl halides or benzyl halides in the presence of sodium hydride got C4-alkylated isoquinolinone derivatives. However, the synthesis of quinazoline derivatives began with a condensation of methyl 2-aminobenzoate (36) with urea under high temperature. The cyclized product, quinazoline-2,4(1H,3H)-dione (37), was then treated with phosphorus oxychloride to obtain 2,4-dichloroquinazoline (38). Compound 38 was treated with sodium hydroxide solution lead to the formation of 39. Subsequently, compound 40 was provided by the sealed tube reaction of secondary amines with 39 under high temperature. The designed isoquinolinone derivatives were subjected to neurite outgrowth evaluation. The preliminary results demonstrated that 3-(piperidin-1-yl) isoquinolin-1(2H)-one (17) and its derivatives such as (R)-3-(3-(N-Boc-amino)piperidin-1-yl)isoquinolin-1(2H)-one (8), significantly promote in vivo neurite outgrowth at sub-μM range but less activity of DPP 4 inhibition. These isoquinolinone derivatives provide an alternative strategy which may be applied to therapeutically interest for handling neurodegenerative disorders and diabetes mellitus after better optimization. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T02:24:49Z (GMT). No. of bitstreams: 1 ntu-98-R96423015-1.pdf: 1432344 bytes, checksum: 46468c5912905849c71649db369c564c (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | Abstract……………………………………………………………………………………………5
Chinese Abstract…………………………………………………………………..........................6 I. Introduction……………………………………………………………………………………7 1.1 Neuron degeneration………………………………………………………………………..7 1.2 Neurodegenerative disorders associated with diabetes mellitus……………………….…..10 II. Design of target compound…………………………………………………….…………...18 III. Result and discussion………………………………………………………………………22 3.1 Synthesis of target compound……………………………………………………………..22 3.1.1 The synthesis of isoquinolinone analogues………………………………………….22 3.1.2 The synthesis of 4-oxo-5,6,7,8-tetrahydroquinazolin analogues…………………....29 3.1.3 The synthesis of quinazolinone analogues ………………………………………….30 3.2 Biological Evaluation……………………………………………………………………..32 3.2.1 Neurite outgrowth assay……………………………………………………………..32 3.2.2 DPPs assay…………………………………………………………………………...38 3.2.3 TrkA binding assay and western blots of neurotrophic factors……………………...40 3.2.4 Analysis of neurotrophic-nonamyloidogenic effect……………………………....43 IV. Conclusion……………………………………………………………………………………45 V. Experimental section ……………………………………………………………….…...46 5.1 Experimental Instrument and examination method………………………………………..46 5.2 Reagent and chemical compound………………………………………………………….46 5.3 Synthesis method…………………………………………………………………………..46 VI. Reference……………………………………………………………………………………..53 | |
dc.language.iso | en | |
dc.title | 神經滋養調控劑之合成設計與生物活性評估 | zh_TW |
dc.title | Design, Synthesis and Evaluation of Neurotrophic Modulators | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王光昭,忻凌偉,孔繁璐,楊家榮 | |
dc.subject.keyword | 神經滋養調控劑, | zh_TW |
dc.subject.keyword | Neurotrophic Modulators, | en |
dc.relation.page | 56 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 1.4 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。